News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HIV Antibodies That are Worth the Wait, Rockefeller University and California Institute of Technology Study


4/1/2013 7:47:27 AM

An effective vaccine against HIV-1 remains elusive, but one promising strategy focuses on designer antibodies that have much broader potency than most normal, exquisitely specific antibodies. These broadly neutralizing antibodies (bNAbs) can handle the high mutation rate of HIV particles that makes normal, very specific antibodies useless within a short space of time. A study published by Cell Press on March 28th in the journal Cell reveals surprising mutations in these antibodies that are crucial for strong protection against HIV-1. The findings could guide efforts to design better HIV-1 vaccines.

Read at EurekAlert!
Read at MedicalXpress

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES